BRCA1-Dependent Translational Regulation in Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Dacheux, Estelle ^a,b,c,d   Vincent, Anne ^a,b,c,d   Nazaret, Nicolas ^e   Combet, Christophe ^a,f   Wierinckx, Anne ^a,b,c,e   Mazoyer, Sylvie ^a,b,c,d   Diaz, Jean Jacques ^a,b,c   Lachuer, Joël ^a,b,c,e   Da Venezia, Nicolella ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d Equipe Labellisée Ligue Nationale Contre le Cancer   (France)

^e ProfileXpert   (France)

^f INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA; POLYADENYLIC ACID BINDING PROTEIN; BRCA1 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION; GENE IDENTIFICATION; HIPK2 GENE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INTERACTION; SMC6 GENE; THRA GENE; TOP1 GENE; TRANSLATION INITIATION; TRANSLATION REGULATION; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; PROTEIN SYNTHESIS;

BIOMARKERS, TUMOR; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MCF-7 CELLS; POLY(A)-BINDING PROTEIN I; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84879270653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067313     Document Type: Article

References (63)

1. Stratton MR, Rahman N, (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17-22.
2. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122.
3. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ, (1999) Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer 80: 823-826.
4. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, et al. (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39: 857-865.
5. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21: 236-240.
6. Venkitaraman AR, (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
7. Fabbro M, Henderson BR, (2003) Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282: 59-69.
8. Wang H, Yang ES, Jiang J, Nowsheen S, Xia F, (2010) DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res 70: 6258-6267.
9. Okada S, Ouchi T, (2003) Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 278: 2015-2020.
10. Fabbro M, Schuechner S, Au WW, Henderson BR, (2004) BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Exp Cell Res 298: 661-673.
11. Yang ES, Xia F, (2010) BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS J 277: 3079-3085.
12. Dizin E, Ray H, Suau F, Voeltzel T, Dalla Venezia N, (2008) Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis. Apoptosis 13: 237-246.
13. Laulier C, Barascu A, Guirouilh-Barbat J, Pennarun G, Le Chalony C, et al. (2011) Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res 71: 3590-3602.
14. Dizin E, Gressier C, Magnard C, Ray H, Decimo D, et al. (2006) BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation. J Biol Chem 281: 24236-24246.
15. Scully R, Chen J, Plug A, Xiao Y, Weaver D, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275.
16. Belin S, Hacot S, Daudignon L, Therizols G, Pourpe S, et al. (2010) Purification of ribosomes from human cell lines. Curr Protoc Cell Biol Chapter 3: Unit 3 40.
17. Nguyen-Lefebvre AT, Gonin-Giraud S, Scherl A, Arboit P, Granger L, et al. (2011) Identification of human, rat and chicken ribosomal proteins by a combination of two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. J Proteomics 74: 167-185.
18. Rivera CI, Lloyd RE, (2008) Modulation of enteroviral proteinase cleavage of poly(A)-binding protein (PABP) by conformation and PABP-associated factors. Virology 375: 59-72.
19. Nousch M, Reed V, Bryson-Richardson RJ, Currie PD, Preiss T, (2007) The eIF4G-homolog p97 can activate translation independent of caspase cleavage. RNA 13: 374-384.
20. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, et al. (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281: 3172-3181.
21. Brunet J, Vazquez-Martin A, Colomer R, Grana-Suarez B, Martin-Castillo B, et al. (2008) BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 47: 157-163.
22. Hakem R, de la Pompa JL, Mak TW, (1998) Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia 3: 431-445.
23. Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, et al. (2012) Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics 11: M111 013334.
24. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA, (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204.
25. Hofmann TG, Glas C, Bitomsky N, (2013) HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays 35: 55-64.
26. D'Orazi G, Rinaldo C, Soddu S, (2012) Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res 31: 63.
27. Ortega FJ, Moreno-Navarrete JM, Mayas D, Garcia-Santos E, Gomez-Serrano M, et al. (2012) Breast cancer 1 (BrCa1) may be behind decreased lipogenesis in adipose tissue from obese subjects. PLoS One 7: e33233.
28. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, et al. (2011) Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res 39: 9536-9548.
29. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, et al. (2010) BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 122: 721-731.
30. Lamber EP, Horwitz AA, Parvin JD, (2010) BRCA1 represses amphiregulin gene expression. Cancer Res 70: 996-1005.
31. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, et al. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292: 929-934.
32. Qin X, Sarnow P, (2004) Preferential translation of internal ribosome entry site-containing mRNAs during the mitotic cycle in mammalian cells. J Biol Chem 279: 13721-13728.
33. Thomas JD, Johannes GJ, (2007) Identification of mRNAs that continue to associate with polysomes during hypoxia. RNA 13: 1116-1131.
34. Bushell M, Stoneley M, Kong YW, Hamilton TL, Spriggs KA, et al. (2006) Polypyrimidine tract binding protein regulates IRES-mediated gene expression during apoptosis. Mol Cell 23: 401-412.
35. Powley IR, Kondrashov A, Young LA, Dobbyn HC, Hill K, et al. (2009) Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes. Genes Dev 23: 1207-1220.
36. Kawai T, Fan J, Mazan-Mamczarz K, Gorospe M, (2004) Global mRNA stabilization preferentially linked to translational repression during the endoplasmic reticulum stress response. Mol Cell Biol 24: 6773-6787.
37. Spriggs KA, Stoneley M, Bushell M, Willis AE, (2008) Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 100: 27-38.
38. Komar AA, Hatzoglou M, (2011) Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 10: 229-240.
39. King HA, Cobbold LC, Willis AE, (2010) The role of IRES trans-acting factors in regulating translation initiation. Biochem Soc Trans 38: 1581-1586.
40. Lewis SM, Holcik M, (2008) For IRES trans-acting factors, it is all about location. Oncogene 27: 1033-1035.
41. Lewis SM, Veyrier A, Hosszu Ungureanu N, Bonnal S, Vagner S, et al. (2007) Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation. Mol Biol Cell 18: 1302-1311.
42. Lin JC, Hsu M, Tarn WY, (2007) Cell stress modulates the function of splicing regulatory protein RBM4 in translation control. Proc Natl Acad Sci U S A 104: 2235-2240.
43. Pesole G, Liuni S, Grillo G, Licciulli F, Larizza A, et al. (2000) UTRdb and UTRsite: specialized databases of sequences and functional elements of 5′ and 3′ untranslated regions of eukaryotic mRNAs. Nucleic Acids Res 28: 193-196.
44. Sombroek D, Hofmann TG, (2009) How cells switch HIPK2 on and off. Cell Death Differ 16: 187-194.
45. Wei G, Ku S, Ma GK, Saito S, Tang AA, et al. (2007) HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A 104: 13040-13045.
46. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, et al. (2008) High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 27: 4745-4751.
47. Al-Beiti MA, Lu X, (2008) Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis. Aust N Z J Obstet Gynaecol 48: 329-336.
48. De Piccoli G, Torres-Rosell J, Aragon L, (2009) The unnamed complex: what do we know about Smc5-Smc6? Chromosome Res 17: 251-263.
49. Potts PR, Yu H, (2007) The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol 14: 581-590.
50. Lin NU, Eierman W, Greil R, Campone M, Kaufman B, et al. (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105: 613-620.
51. Sordet O, Larochelle S, Nicolas E, Stevens EV, Zhang C, et al. (2008) Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J Mol Biol. 381: 540-549.
52. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
53. Nagai MA, Yamamoto L, Salaorni S, Pacheco MM, Brentani MM, et al. (1994) Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes Chromosomes Cancer 11: 58-62.
54. Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, et al. (2011) Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res 13: R15.
55. Zhu X, Cheng SY, (2010) New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes 17: 408-413.
56. Ray H, Moreau K, Dizin E, Callebaut I, Venezia ND, (2006) ACCA phosphopeptide recognition by the BRCT repeats of BRCA1. J Mol Biol 359: 973-982.
57. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, et al. (2002) BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21: 6729-6739.
58. Hauge H, Patzke S, Aasheim HC, (2007) Characterization of the FAM110 gene family. Genomics 90: 14-27.
59. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, et al. (2012) Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat 132: 1063-1072.
60. Lange CA, Yee D, (2011) Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 18: C19-24.
61. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30: 282-290.
62. Bilanges B, Stokoe D, (2007) Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 26: 5973-5990.
63. Silvera D, Formenti SC, Schneider RJ, (2010) Translational control in cancer. Nat Rev Cancer 10: 254-266.